!!! SOLAGRAN !!! - Durchbruch bei Pharmakonzern - 500 Beiträge pro Seite
eröffnet am 18.07.07 08:03:24 von
neuester Beitrag 05.09.07 07:34:45 von
neuester Beitrag 05.09.07 07:34:45 von
Beiträge: 4
ID: 1.130.481
ID: 1.130.481
Aufrufe heute: 0
Gesamt: 2.634
Gesamt: 2.634
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 6793 | |
| vor 1 Stunde | 3058 | |
| vor 1 Stunde | 2848 | |
| vor 53 Minuten | 1265 | |
| vor 1 Stunde | 1244 | |
| vor 1 Stunde | 1077 | |
| 08.05.24, 11:56 | 964 | |
| vor 1 Stunde | 934 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 2. | 6,3400 | -1,18 | 107 | |||
| 2. | 1. | 18.671,52 | -0,37 | 69 | |||
| 3. | 3. | 168,80 | -1,79 | 59 | |||
| 4. | 4. | 9,9500 | -3,59 | 53 | |||
| 5. | 21. | 9,5800 | +0,52 | 52 | |||
| 6. | 9. | 0,1589 | +1,53 | 32 | |||
| 7. | 23. | 0,0208 | +36,84 | 29 | |||
| 8. | 7. | 69.938,94 | -1,65 | 28 |
Feedback
Solagran Limited
ACN 002 592 396
Level 11
492 St Kilda Road
Melbourne 3004
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155
18 July, 2007
Company Announcement
Pharmaceutical Registration of Bioeffective® R and Ropren
The Directors of Solagran Limited are pleased to announce that the Company has received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both the substance Bioeffective® R and the medicine Ropren has been finalised. The Directors regard this as a tremendous achievement after an intense four year effort.
Solagran is now free to promote Ropren in Russia as a highly effective treatment for chronic liver disease. Solagran will now focus on scaling up production facilities sufficient to meet the expected demand in Russia. It can also now initiate the next stage of its Ropren strategy which is to obtain pharmaceutical registration in the European Union as a precursor to taking it to North America and Asia........
http://www.asx.com.au/asxpdf/20070718/pdf/313hddj46bky9j.pdf
ACN 002 592 396
Level 11
492 St Kilda Road
Melbourne 3004
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155
18 July, 2007
Company Announcement
Pharmaceutical Registration of Bioeffective® R and Ropren
The Directors of Solagran Limited are pleased to announce that the Company has received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both the substance Bioeffective® R and the medicine Ropren has been finalised. The Directors regard this as a tremendous achievement after an intense four year effort.
Solagran is now free to promote Ropren in Russia as a highly effective treatment for chronic liver disease. Solagran will now focus on scaling up production facilities sufficient to meet the expected demand in Russia. It can also now initiate the next stage of its Ropren strategy which is to obtain pharmaceutical registration in the European Union as a precursor to taking it to North America and Asia........
http://www.asx.com.au/asxpdf/20070718/pdf/313hddj46bky9j.pdf
03/08/2007 Change of Directors` Interest Notice
http://www.asx.com.au/asxpdf/20070803/pdf/313t1ffx7lvdd4.pdf
Solagran Limited
ACN 002 592 396
Level 11
492 St Kilda Road
Melbourne 3004
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155
5 September, 2007
Company Announcement
Distribution Partnerships for Bioeffectives A and B
http://www.asx.com.au/asxpdf/20070905/pdf/314dcw40b42wkm.pdf
ACN 002 592 396
Level 11
492 St Kilda Road
Melbourne 3004
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155
5 September, 2007
Company Announcement
Distribution Partnerships for Bioeffectives A and B
http://www.asx.com.au/asxpdf/20070905/pdf/314dcw40b42wkm.pdf
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 106 | ||
| 74 | ||
| 56 | ||
| 52 | ||
| 49 | ||
| 32 | ||
| 28 | ||
| 27 | ||
| 26 | ||
| 26 |
| Wertpapier | Beiträge | |
|---|---|---|
| 24 | ||
| 23 | ||
| 22 | ||
| 22 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 16 |
